Evidence map›Paper›PMID 34889514›Full record

ArticlePediatric blood & cancer2022

Association between fatigue and sleep disturbances during treatment for pediatric acute lymphoblastic leukemia and posttreatment neurocognitive performance.

Priscilla Vasquez, Johanna Escalante, Kimberly P Raghubar, Lisa S Kahalley, Olga A Taylor, Ida Ki Moore, Marilyn J Hockenberry, Michael E Scheurer, Austin L Brown

Open access · greenAbstract read
In one paragraph

Article in Pediatric blood & cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Priscilla VasquezDepartment of Pediatrics, Section of Oncology, Baylor College of Medicine, Houston, Texas, USA.
Johanna EscalanteDepartment of Pediatrics, Section of Psychology, Baylor College of Medicine, Houston, Texas, USA.
Kimberly P RaghubarDepartment of Pediatrics, Section of Psychology, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0002-9332-181X
Lisa S KahalleyDepartment of Pediatrics, Section of Psychology, Baylor College of Medicine, Houston, Texas, USA.
Olga A TaylorDepartment of Pediatrics, Section of Oncology, Baylor College of Medicine, Houston, Texas, USA.
Ida Ki MooreCollege of Nursing, University of Arizona, Tuscan, Arizona, USA.
Marilyn J HockenberryDepartment of Pediatrics, Section of Oncology, Baylor College of Medicine, Houston, Texas, USA.
Michael E ScheurerDepartment of Pediatrics, Section of Oncology, Baylor College of Medicine, Houston, Texas, USA.
Austin L BrownDepartment of Pediatrics, Section of Oncology, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0001-5802-5073
Baylor College of Medicine · USUniversity of Arizona · US

Funding

Phenotype-Genotype Associations with Symptoms During Childhood Leukemia TreatmentR01CA169398 · NCI · DUKE UNIVERSITY · PI HOCKENBERRY, MARILYN J, SCHEURER, MICHAEL E. · 2012 to 2016
$2.9M
Integrative Molecular Epidemiology of Neurocognitive Outcomes in Acute Lymphoblastic LeukemiaK07CA218362 · NCI · BAYLOR COLLEGE OF MEDICINE · PI BROWN, AUSTIN L · 2018 to 2022
$758k
NCI NIH HHS K07 CA218362NCI NIH HHS R01 CA169398
6 · The paper itself

Abstract

backgroundSurvivors of pediatric acute lymphoblastic leukemia (ALL) are at increased risk of neurocognitive weakness in the areas of attention, executive function, and processing speed. Although fatigue and sleep disturbances are frequent complications of ALL therapy and associated with cognitive functions, the impact of fatigue and sleep profiles during active ALL treatment on posttreatment neurocognitive performance has received limited attention.

methodsPediatric patients (n = 120) with ALL (diagnosed 2011-2016) who completed fatigue and sleep questionnaires at four time points during active treatment were enrolled in a study of neurocognitive performance. Latent class growth analysis identified subgroups of patients with similar sleep and fatigue profiles during treatment. Neurocognitive performance collected >6 months post treatment on 40 participants was compared between latent classes using multivariable linear regression models.

resultsParticipants (57.5% male and 79.1% Hispanic or non-Hispanic White) were classified into one of two fatigue and sleep profiles: Class 1 characterized by mild fatigue and sleep disturbances during treatment (50.8%), and Class 2 characterized by higher levels of fatigue and sleep disturbances (49.2%). Posttreatment cognitive performance was in the normal range for most measures, but significantly below normative means for executive function, verbal short-term memory, attention, and distractability measures. Compared to Class 1, Class 2 demonstrated significantly (p < .05) poorer posttreatment neurocognitive performance, particularly in measures of attention.

conclusionsOur findings indicate that fatigue and sleep disturbances during the first year of pediatric ALL therapy may impact long-term neurocognitive performance. Sleep and fatigue may be targets for intervention to preserve cognitive functioning in survivors.

Indexed as

Precursor Cell Lymphoblastic Leukemia-LymphomaSleep Wake DisordersChildExecutive FunctionFatigueFemaleHumansMaleNeuropsychological TestsSleepattentionexecutive functionfatiguememoryneurocognitivepediatric acute lymphoblastic leukemiasleep

Identifiers

PMID34889514
PMCPMC8957586
OpenAlexW4200226274

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.